BMO Capital analyst Gary Nachman lowered the firm’s price target on Pacira to $52 from $60 and keeps a Market Perform rating on the shares. The company’s preliminary Q4 product revenue missed expectations, though this was not completely surprising given the October-November results previously provided, the analyst tells investors in a research note. Nachman adds that continued macroeconomic challenges and pricing pressure are weighing on growth despite Pacira indicating that volumes are outperforming flat surgical market.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira price target lowered to $63 from $66 at Needham
- Pacira sees FY22 EPS ‘at least’ $2.50, consensus $2.77
- Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
- Pacira price target lowered to $50 from $54 at Cowen
- Pacira sinks after continuing to not provide outlook with monthly sales
